Alimera Sciences Preço/Valor Contábil
Qual é o Preço/Valor Contábil de Alimera Sciences?
O Preço/Valor Contábil de Alimera Sciences Inc. é 0.36
Qual é a definição de Preço/Valor Contábil?
A razão entre cotação e valor contabilístico representa a razão entre o valor das ações de uma empresa e o valor contábil por ação.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Preço/Valor Contábil de empresas na Setor Health Care em NASDAQ em comparação com Alimera Sciences
O que Alimera Sciences faz?
alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
Empresas com preço/valor contábil semelhantes a Alimera Sciences
- NWS tem Preço/Valor Contábil de 0.36
- Koenig & Bauer AG tem Preço/Valor Contábil de 0.36
- Best Pacific International tem Preço/Valor Contábil de 0.36
- Bambuser AB (publ) tem Preço/Valor Contábil de 0.36
- Gravity (India) tem Preço/Valor Contábil de 0.36
- Gemdale Properties and Investment tem Preço/Valor Contábil de 0.36
- Alimera Sciences tem Preço/Valor Contábil de 0.36
- Tritax EuroBox plc tem Preço/Valor Contábil de 0.36
- Vasta Platform tem Preço/Valor Contábil de 0.36
- EyePoint Pharmaceuticals Inc tem Preço/Valor Contábil de 0.36
- Valeura tem Preço/Valor Contábil de 0.36
- Devernois S.A tem Preço/Valor Contábil de 0.36
- Inozyme Pharma tem Preço/Valor Contábil de 0.37